Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:AZRX NYSE:IBIO NASDAQ:OBSV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.81-3.2%$0.74$0.38▼$215.31$9.18M0.711.86 million shs131,524 shsAZRXAzurRx BioPharma$0.49-0.6%$4.04$3.36▼$26.30$4.59M1.51628,703 shs33,544 shsIBIOiBio$0.74-2.8%$0.81$0.64▼$6.89$12.22M0.941.50 million shs217,915 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs250 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-3.24%+4.24%+14.69%+88.66%-99.58%AZRXAzurRx BioPharma-0.60%+9.01%-1.75%+30.58%-50.84%IBIOiBio-2.77%+1.32%-1.12%-19.52%-65.76%OBSVObsEva0.00%0.00%-75.00%-75.00%-75.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma2.6961 of 5 stars3.52.00.00.00.61.71.9AZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.5202 of 5 stars3.50.00.00.01.10.00.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0044,234.98% UpsideAZRXAzurRx BioPharma 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00576.04% UpsideOBSVObsEva 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AZRX, IBIO, AEON, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AIBIOiBio$375K32.58N/AN/A$1.41 per share0.52OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.124.51N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)AZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ALatest AZRX, IBIO, AEON, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/AAEONAEON Biopharma-$11.51N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22AZRXAzurRx BioPharmaN/A1.331.33IBIOiBio0.051.761.76OBSVObsEvaN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%AZRXAzurRx BioPharma6.27%IBIOiBio7.90%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%AZRXAzurRx BioPharma7.30%IBIOiBio0.58%OBSVObsEva14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableIBIOiBio10016.52 million9.82 millionN/AOBSVObsEva5077.97 million66.74 millionNot OptionableAZRX, IBIO, AEON, and OBSV HeadlinesRecent News About These CompaniesObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantAugust 31, 2024 | pharmaphorum.comPObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 3, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsMarch 19, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 28, 2024 | globenewswire.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesFebruary 25, 2024 | benzinga.comObsEva SA OBSNNovember 11, 2023 | morningstar.comMObsEva SA OBSEFNovember 11, 2023 | morningstar.comMObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserverMay 10, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo FinanceMay 2, 2023 | news.google.comNObsEva Says Fabien De Ladonchamps Is New CEO - NasdaqMay 2, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswireMay 2, 2023 | news.google.comNGameto Appoints Teri Loxam as Chief Financial Officer - citybizApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Marketscreener.comApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Yahoo FinanceApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - BenzingaApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - EIN NewsApril 28, 2023 | news.google.comNGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR NewswireApril 28, 2023 | news.google.comNEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital JournalApril 26, 2023 | news.google.comNEndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPRApril 23, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZRX, IBIO, AEON, and OBSV Company DescriptionsAEON Biopharma NASDAQ:AEON$0.81 -0.03 (-3.24%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$0.81 0.00 (-0.37%) As of 07/24/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.AzurRx BioPharma NASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.iBio NYSE:IBIO$0.74 -0.02 (-2.77%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$0.73 -0.01 (-0.89%) As of 07/24/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
